Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Emerg Infect Dis ; 29(4): 860-862, 2023 04.
Article in English | MEDLINE | ID: mdl-36918376

ABSTRACT

A 26-year-old patient in France who worked as a butcher sought care initially for erythema multiforme. Clinical examination revealed a nodule with a crusty center, which upon investigation appeared to be an orf nodule. Diagnosis was confirmed by PCR. The patient was not isolated and had a favorable outcome after basic wound care.


Subject(s)
Ecthyma, Contagious , Erythema Multiforme , Mpox (monkeypox) , Animals , Sheep , Humans , Adult , Ecthyma, Contagious/diagnosis , Ecthyma, Contagious/epidemiology , Erythema Multiforme/diagnosis , Erythema Multiforme/epidemiology , France/epidemiology , Disease Outbreaks
2.
Infection ; 49(4): 781-783, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33387262

ABSTRACT

BACKGROUND: We report here the case of two coworkers infected by the same SARS-CoV-2 strain, presenting two different immunological outcomes. CASE: One patient presented a strong IgG anti-receptor-binding domain immune response correlated with a low and rapidly decreasing titer of neutralizing antibodies. The other patient had a similar strong IgG anti-receptor-binding domain immune response but high neutralizing antibody titers. DISCUSSION AND CONCLUSION: Thus, host individual factors may be the main drivers of the immune response varying with age and clinical severity.


Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , COVID-19/immunology , Immunoglobulin G/blood , Infectious Disease Transmission, Patient-to-Professional , SARS-CoV-2/immunology , Adult , Antibodies, Neutralizing/biosynthesis , COVID-19/transmission , Cross Infection/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/biosynthesis , Male , Middle Aged , Nasopharynx/virology , SARS-CoV-2/classification , SARS-CoV-2/genetics
3.
NPJ Vaccines ; 3: 14, 2018.
Article in English | MEDLINE | ID: mdl-29707242

ABSTRACT

Rift Valley fever virus, a phlebovirus endemic in Africa, causes serious diseases in ruminants and humans. Due to the high probability of new outbreaks and spread to other continents where competent vectors are present, vaccine development is an urgent priority as no licensed vaccines are available outside areas of endemicity. In this study, we evaluated in sheep the protective immunity induced by DNA vaccines encoding the extracellular portion of the Gn antigen which was either or not targeted to antigen-presenting cells. The DNA encoding untargeted antigen was the most potent at inducing IgG responses, although not neutralizing, and conferred a significant clinical and virological protection upon infectious challenge, superior to DNA vaccines encoding the targeted antigen. A statistical analysis of the challenge parameters supported that the anti-eGn IgG, rather than the T-cell response, was instrumental in protection. Altogether, this work shows that a DNA vaccine encoding the extracellular portion of the Gn antigen confers substantial-although incomplete-protective immunity in sheep, a natural host with high preclinical relevance, and provides some insights into key immune correlates useful for further vaccine improvements against the Rift Valley fever virus.

4.
Viruses ; 10(1)2017 12 23.
Article in English | MEDLINE | ID: mdl-29295488

ABSTRACT

Since the official declaration of smallpox eradication in 1980, the general population vaccination has ceased worldwide. Therefore, people under 40 year old are generally not vaccinated against smallpox and have no cross protection against orthopoxvirus infections. This naïve population may be exposed to natural or intentional orthopoxvirus emergences. The virology unit of the Institut de Recherche Biomédicale des Armées (France) has developed research programs on orthopoxviruses since 2000. Its missions were conceived to improve the diagnosis capabilities, to foster vaccine development, and to develop antivirals targeting specific viral proteins. The role of the virology unit was asserted in 2012 when the responsibility of the National Reference Center for the Orthopoxviruses was given to the unit. This article presents the evolution of the unit activity since 2000, and the past and current research focusing on orthopoxviruses.


Subject(s)
Communicable Disease Control/trends , Orthopoxvirus/physiology , Poxviridae Infections/prevention & control , Poxviridae Infections/virology , Research/trends , Animals , Antiviral Agents/chemical synthesis , Antiviral Agents/pharmacology , Antiviral Agents/supply & distribution , France , Humans , Orthopoxvirus/classification , Orthopoxvirus/drug effects , Orthopoxvirus/genetics , Poxviridae/classification , Poxviridae/genetics , Poxviridae Infections/diagnosis , Poxviridae Infections/pathology , Smallpox Vaccine/administration & dosage , Smallpox Vaccine/biosynthesis , Smallpox Vaccine/supply & distribution , Viral Proteins/chemistry , Viral Proteins/drug effects
5.
Virologie (Montrouge) ; 20(4): 218-230, 2016 Aug 01.
Article in English | MEDLINE | ID: mdl-32260034

ABSTRACT

Parapoxviruses, double-stranded DNA viruses of the Poxviridæ family, are etiologic agents of cutaneaous infectious diseases among farm animals. These highly contagious viruses are responsible for wide outbreaks among livestock. The clinical manifestations are generally mild and consist of cutaneous or mucosal lesions, which resolve spontaneously within a few weeks. However, secondary bacterial or fungal infections on the lesion sites can aggravate the symptoms. Sore lesions located within the oral cavity and on the udders can impair feeding or nursing, thus leading to death. Livestock parapoxviruses can infect humans by direct or indirect transmission and affect mainly farmers, slaughters and veterinarians. Human symptoms generally consist of small cutaneous lesions located at the inoculation points but more severe forms can occur, peculiarly in immunocompromised persons. The parapoxvirus epidemiology is poorly understood: their respective host range and ecology among wild animals are to be clarified. The identification of parapoxviruses among marine mammals suggests that the genetic diversity within the genus is still underestimated.

6.
Emerg Infect Dis ; 19(12): 1996-9, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24274113

ABSTRACT

We investigated 4 related human cases of cowpox virus infection reported in France during 2011. Three patients were infected by the same strain, probably transmitted by imported pet rats, and the fourth patient was infected by another strain. The 2 strains were genetically related to viruses previously isolated from humans with cowpox infection in Europe.


Subject(s)
Cowpox virus/classification , Cowpox virus/genetics , Cowpox/epidemiology , Adult , Animals , Cell Line , Child , Cowpox/transmission , Cowpox virus/isolation & purification , Female , France/epidemiology , Genome, Viral , Humans , Male , Molecular Sequence Data , Phylogeny , Rats
7.
J Virol ; 85(10): 5016-26, 2011 May.
Article in English | MEDLINE | ID: mdl-21367889

ABSTRACT

The vaccinia virus (VACV) Lister strain was one of the vaccine strains that enabled smallpox eradication. Although the strain is most often harmless, there have been numerous incidents of mild to life-threatening accidents with this strain and others. In an attempt to further attenuate the Lister strain, we investigated the role of 5 genomic regions known to be deleted in the modified VACV Ankara (MVA) genome in virulence in immunodeficient mice, immunogenicity in immunocompetent mice, and vaccine efficacy in a cowpox virus challenge model. Lister mutants were constructed so as to delete each of the 5 regions or various combinations of these regions. All of the mutants replicated efficiently in tissue culture except region I mutants, which multiplied more poorly in human cells than the parental strain. Mutants with single deletions were not attenuated or only moderately so in athymic nude mice. Mutants with multiple deletions were more highly attenuated than those with single deletions. Deleting regions II, III, and V together resulted in total attenuation for nude mice and partial attenuation for SCID mice. In immunocompetent mice, the Lister deletion mutants induced VACV specific humoral responses equivalent to those of the parental strain but in some cases lower cell-mediated immune responses. All of the highly attenuated mutants protected mice from a severe cowpox virus challenge at low vaccine doses. The data suggest that several of the Lister mutants combining multiple deletions could be used in smallpox vaccination or as live virus vectors at doses equivalent to those used for the traditional vaccine while displaying increased safety.


Subject(s)
Sequence Deletion , Smallpox Vaccine/genetics , Smallpox Vaccine/immunology , Vaccinia virus/genetics , Animals , Antibodies, Viral/blood , Cell Line , Cowpox/prevention & control , Cowpox/virology , Cowpox virus/immunology , Cowpox virus/pathogenicity , Disease Models, Animal , Female , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , Mice, SCID , Vaccines, Attenuated/genetics , Vaccines, Attenuated/immunology , Virus Replication
8.
Vaccine ; 26(14): 1794-804, 2008 Mar 25.
Article in English | MEDLINE | ID: mdl-18336966

ABSTRACT

This study assessed three non-replicating smallpox vaccine candidates (modified vaccinia Ankara (MVA), NYVAC and HR) for their immunogenicity and ability to protect mice against an intranasal cowpox virus challenge and compared them with the traditional replicating vaccine. A single immunisation with the non-replicating vaccines induced a complete protection from death at short-term, but was not fully protective when mice were challenged 150 days post-vaccination with protection correlated with the specific neutralizing antibodies and CD4(+) T-cells responses. Prime-boost vaccination enabled effective long-term protection from death for mice vaccinated with MVA, but protection from disease and CD4(+) T-cell level were lower than the ones induced by the traditional vaccine over the long-term period. Further investigations are necessary with MVA to determine the optimal conditions of immunisation to induce at long-term immunogenicity and protection observed with the 1st generation smallpox vaccine.


Subject(s)
Smallpox Vaccine/immunology , Smallpox/immunology , Smallpox/prevention & control , Animals , Antibody Formation/immunology , Cowpox virus/immunology , Cytokines/biosynthesis , Dendritic Cells/metabolism , Female , Immunity, Cellular/immunology , Immunization, Secondary , Immunohistochemistry , Lung/virology , Mice , Mice, Inbred BALB C , Neutralization Tests , Smallpox/mortality , Smallpox Vaccine/adverse effects , Time Factors , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/immunology , Variola virus/genetics , Variola virus/immunology , Virus Replication
9.
Vaccine ; 25(49): 8290-7, 2007 Nov 28.
Article in English | MEDLINE | ID: mdl-17964011

ABSTRACT

It is now difficult to manufacture the first-generation smallpox vaccine, as the process could not comply with current safety and manufacturing regulations. In this study, a candidate non-clonal second-generation smallpox vaccine developed by Sanofi-Pasteur from the Lister strain has been assessed using a cowpox virus challenge in mice. We have observed similar safety, immunogenicity and protection (from disease and death) after a short or long interval following vaccination, as well as similar virus clearance post-challenge, with the second-generation smallpox vaccine candidate as compared to the traditional vaccine used as a benchmark.


Subject(s)
Antibodies, Viral/blood , Cowpox virus/pathogenicity , Cowpox/prevention & control , Smallpox Vaccine , Vaccinia virus/immunology , Animals , Bioterrorism , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Cells, Cultured , Chick Embryo , Chlorocebus aethiops , Cowpox/immunology , Cowpox/mortality , Female , Humans , Interferon-gamma/biosynthesis , Mice , Mice, Inbred BALB C , Neutralization Tests , Smallpox/immunology , Smallpox/mortality , Smallpox/prevention & control , Smallpox Vaccine/administration & dosage , Smallpox Vaccine/adverse effects , Smallpox Vaccine/immunology , Vaccinia virus/classification , Vero Cells
10.
Vaccine ; 25(25): 4809-17, 2007 Jun 15.
Article in English | MEDLINE | ID: mdl-17499401

ABSTRACT

The intranasal infection of mice with cowpox virus (CPXV) has been evaluated as a model for smallpox infection in man. Administration of a lethal dose of CPXV allowed time for development of T-cell responses but antibodies could not be detected before death occurred. In contrast, infection with a sublethal dose was associated with an early T-cell response followed by neutralising antibodies which correlated with virus clearance. Comparison of two first generation smallpox vaccines revealed no significant differences in terms of immunogenicity, protection and post-challenge virus clearance. These studies show that the CPXV/mouse model is valuable for the initial assessment of smallpox vaccines.


Subject(s)
Cowpox virus/immunology , Cowpox/immunology , Smallpox Vaccine/immunology , Administration, Intranasal , Animals , Antibodies, Viral/analysis , Antibodies, Viral/biosynthesis , Antibody Formation/immunology , Antibody Specificity , Cytokines/biosynthesis , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Female , Immunity, Cellular/immunology , Lung/immunology , Lung/virology , Lymphocytes/immunology , Mice , Spleen/immunology , Spleen/virology , Virus Replication
11.
Clin Chem ; 53(4): 606-13, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17332145

ABSTRACT

BACKGROUND: Variola virus (family Poxviridae, genus Orthopoxvirus) and the closely related cowpox, vaccinia, and monkeypox viruses can infect humans. Efforts are mounting to replenish the smallpox vaccine stocks, optimize diagnostic methods for poxviruses, and develop new antivirals against smallpox, because it is feared that variola virus might be used as a weapon of bioterrorism. METHODS: We developed an assay for the detection of variola virus DNA. The assay is based on TaqMan chemistry targeting the 14-kD protein gene. For the 1st stage of the assay we used genus consensus primers and a mixture of 2 probes (14-kD POX and 14-kD VAR) spanning the 14-kD protein-encoding gene for detection of all human pathogenic orthopoxviruses. We then tested positive samples with the specific orthopoxvirus-specific probe 14-kD POX to identify monkeypox, cowpox, and vaccinia viruses and with the 14-kD VAR probe to identify variola viruses. The assay was established on 4 different PCR cycler platforms. It was assessed in a study with 85 different orthopoxvirus species and strains that included variola, camelpox, cowpox, monkeypox, and vaccinia viruses at concentrations ranging from 100 ng/L to 1 microg/L. RESULTS: The assay detected as little as 0.05 fg of DNA, corresponding to 25 copies of DNA, and enabled differentiation of variola virus from the other orthopoxviruses. CONCLUSIONS: This real-time PCR assay provides a rapid method for the early detection and differentiation of smallpox and other human pathogenic orthopoxvirus infections.


Subject(s)
DNA, Viral/analysis , Genome, Viral , Orthopoxvirus/classification , Viral Proteins/genetics , Base Sequence , Humans , Orthopoxvirus/genetics , Polymerase Chain Reaction , Sensitivity and Specificity , Sequence Alignment , Variola virus/classification , Variola virus/genetics , Virology/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...